Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS AMPLIFICATION
(
ENST00000256078.10 )
KRAS AMPLIFICATION ( ENST00000256078.10 ) - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035).
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1497
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/592
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Carboplatin,Sorafenib,Docetaxel
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26307133
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Carboplatin | Sensitivity | true |
| Docetaxel | Sensitivity | true |
| Sorafenib | Sensitivity | true |